Product Description
Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01280591)
Mechanisms of Action: COX1 Inhibitor, COX2 Inhibitor, H1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pain Unspecified|Toothache|Pain, Postoperative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Morpheus/DPH | P3 |
Completed |
Toothache|Pain, Postoperative |
2012-02-01 |
2019-03-19 |
Treatments |
|
| MUST | P3 |
Completed |
Pain Unspecified |
2011-07-01 |
2019-03-19 |
Treatments |